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Abstract 
Cyclic disulfide-rich peptides have exceptional stability and are promising frameworks for drug design. We 
were interested in obtaining X-ray structures of these peptides to assist in drug design applications but 
disulfide-rich peptides can be notoriously difficult to crystallize. To overcome this limitation we chemically 
synthesized the L- and D-forms of three prototypic cyclic disulfide-rich peptides: SFTI-1 (14-mer with one 
disulfide bond), cVc1.1 (22-mer with two disulfide bonds) and kB1 (29-mer with three disulfide bonds) for 
racemic crystallization studies. Facile crystal formation occurred from a racemic mixture of each peptide, 
yielding structures solved at resolutions from 1.25 Å to 1.9 Å. Additionally, we obtained the quasi-racemic 
structures of two mutants of kB1, [G6A]kB1 and [V25A]kB1, which were solved at a resolution of 1.25 Å 
and 2.3 Å, respectively. The racemic crystallography approach appears to have broad utility in the structural 
biology of cyclic peptides. 
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Main Text 
Highly constrained peptides are showing exciting potential in drug discovery applications.[1] Of particular 
interest are highly constrained peptides that incorporate disulfide bonds but are additionally stabilized by a 
macrocyclic backbone (Table 1). The combination of two types of topological constraints (backbone 
cyclization and internal cross-linking) underpins the remarkable stability of these peptides and hence their 
potential as drug design scaffolds.[2] We and others have used these scaffolds for stabilizing bioactive 
peptide epitopes through the emerging design paradigm of molecular grafting, as highlighted in recent 
reviews,[2-4] with applications including inflammatory pain,[5] multiple sclerosis[6] and cancer.[7] 
 
Here we focus on three scaffolds. One of the smallest naturally-occurring cyclic disulfide-rich peptides is 
sunflower trypsin inhibitor-1 (SFTI-1), a 14-amino acid peptide containing a single disulfide bond (CysI-
CysII), which is the most potent known peptide inhibitor of trypsin.[8] We have also explored cyclic 
disulfide-rich peptides that are chemically re-engineered from natural acyclic peptides.[2] Cyclic Vc1.1 
(cVc1.1) is a 22-residue peptide containing two disulfide bonds (CysI-CysIII and CysII-CysIV) that is re-
engineered from a cone snail venom peptide.[9] It shows orally delivered activity in a rat model of 
neuropathic pain and is more than two orders of magnitude more potent than gabapentin, the current leading 
oral therapy for neuropathic pain.[9] Kalata B1 (kB1) is the prototypical and one of the most well-studied 
cyclotides, a family of naturally-occurring cyclic disulfide-rich peptides that are characterized by a knotted 
disulfide bond arrangement (CysI-CysIV, CysII-CysV and CysIII-CysVI)[10] and a wide variety of biological 
activities,[11-16] with many potential agrochemical and pharmaceutical applications.  
 
In view of the growing interest in cyclic disulfide-rich peptides, we sought to obtain high-resolution 
structural information for the three prototypical scaffolds, SFTI-1, cVc1.1 and kB1. However, crystallization 
of small peptides is notoriously challenging. A robust method that can be used to facilitate the elucidation of 
high quality atomic resolution structures would therefore be a valuable tool. Herein we explored the 
emerging approach of racemic crystallography, which has been used for overcoming the crystallization 
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'bottleneck' for a range of proteins[17-22] but has not yet been applied to cyclic disulfide-rich peptides. Using 
this approach, we obtained high-resolution structures of a range of cyclic disulfide-rich peptides of varying 
disulfide bond and amino acid content. 
 
We took advantage of modern approaches for chemical synthesis, cyclization and oxidative folding of cyclic 
disulfide-rich peptides, which have generally made the production of large amounts of pure L- and D-
peptides affordable.[23] Synthesis of SFTI-1, cVc1.1, and kB1, as well as their mirror image forms was 
carried out using reported procedures with slight modifications (for details, see Supporting Information). 
The mirror image symmetry of the D-peptide forms with their respective L-peptide forms was confirmed in 
circular dichroism spectra, which showed equal but opposite optical rotation of each enantiomeric peptide 
pair. When each pair of isomers was mixed in equal proportions, the circular dichroism signal of one of the 
isomers was cancelled by the other (Figure 1). 
 
The higher probability of obtaining crystals from racemic mixtures compared to the L-form alone has a 
sound theoretical basis that is supported by several recent experimental observations.[24] We were able to 
obtain diffraction-quality crystals and the crystal structures were determined using the molecular 
replacement method (see Supporting Information). Data collection and refinement statistics are given in 
Supplementary Table 1. The final refined models have been deposited in the Protein Data Bank with the 
codes 4TTK (SFTI-1 racemate), 4TTL (cVc1.1 racemate), 4TTM (kB1 racemate), 4TTN ([G6A]kB1 quasi-
racemate) and 4TTO ([V25A]kB1 quasi-racemate). 
 
As shown in Figure 2a, the X-ray structure of the SFTI-1 true racemate was solved in the centrosymmetric 
space group P-3. This was initially surprising because theoretical calculations predict that P-1 is the most 
likely space group for obtaining racemate structures[24-25] and, also, most current examples of protein/peptide 
racemate structures have been solved in space group P-1,[20-21, 26-31] with P1[17, 32], P21/c[33] and I41/a[34] 
being the other reported examples. The asymmetric unit cell contains a single molecule of the D-form of 
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SFTI-1 (Figure 2b), which adopts a compact tertiary fold that is identical to its inverted L-form. The 
structures of both D- and L-forms of SFTI-1 are stabilized by a series of hydrogen bonds (e.g. D-Phe12 HN to 
D-Arg2 CO, D-Thr4 HN to D-Ile10 CO) and a disulfide bond (CysI-CysII, Figure 2b inset) that compresses the 
overall topology of the cyclic peptide. It has been shown that both the disulfide bond and the cyclic 
backbone are required to maintain the potent trypsin-inhibitory activity of SFTI-1 and its resistance to 
proteolysis.[35] Interestingly, the unit cell contains three molecules of each enantiomer as shown in Figure 
2a; each triplet of enantiomers forms a supramolecular complex that has three-fold symmetry and is 
stabilized by hydrophobic interactions, involving residues D-Ile10 and D-Phe12 for the trimer of D-forms, for 
example, as shown in Figure 2c and 2d. To our knowledge, this is the first description of a possible 
supramolecular complex of SFTI-1, and we postulate that this quaternary structure might have implications 
for its storage state, and possibly its long-term stability, in sunflower seeds. Figure 2e shows a superposition 
of our structure of L-SFTI-1 with the structure of the trypsin-bound L-SFTI-1 (the only other reported X-ray 
structure of SFTI-1), showing that the overall fold is maintained, though deviations in the precise positions 
of several atoms are observed. Generally, this result highlights the rigidity of the SFTI-1 fold and also 
provides validation of the racemic crystallography approach for obtaining high-resolution structures of 
cyclic disulfide-rich peptides. 
 
To examine whether racemic crystallography can be applied to other cyclic disulfide-rich peptides, we 
elucidated the X-ray structure of the cVc1.1 true racemate, which was solved in space group Pbca. As 
shown in Figure 3a, the L- and D-enantiomers are tightly packed in an ordered array. Figure 3b shows a pair 
of the L- and D-enantiomers and highlights some of the residues involved in the packing interface (e.g. Tyr10, 
Asn9 and Pro6; inset). Within the asymmetric unit cell is one L-form of cVc1.1, which is identical in 
structure to the inverted D-form. The structure of L-cVc1.1 displays an α-helix spanning residues Arg7 to 
Asp11; conservation of this structural motif is considered to be important for retaining biological activity.[36] 
Furthermore, the structure is stabilized by two disulfide bonds (CysI-CysIII and CysII-CysIV) that are clearly 
resolved by the electron density (Figure 3c). Residues Gly17 to Gly22 of cVc1.1 form a 'linker' sequence that 
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was introduced to native Vc1.1 to connect its free N- and C-termini to enhance its stability and 
biopharmaceutical properties. Comparison of our structure of the L-enantiomer of cVc1.1 with the solution 
NMR structure of the same peptide identifies some differences in the arrangement of the CysI-CysIII 
disulfide bond as well as the conformation of the linker sequence. As the first X-ray structure of cVc1.1 
(both L- and D-forms), it could be used as a starting point for comprehensive molecular dynamics 
simulations to investigate binding mechanisms to cell surface receptors or as a template for in silico re-
engineering. 
 
The X-ray structure of the true racemate of cyclotide kB1 was solved in space group P-1 and is shown in 
Figure 4a. The unit cell contains two molecules of each enantiomer; a pair of L- and D-enantiomers of kB1, 
which occupy the asymmetric unit cell, is shown in Figure 4b. Comparison of the structures of the L- and 
(inverted) D-forms of kB1 shows that there are slight differences in the side-chain orientations of some 
residues (e.g. orientation of Arg28 compared to that of D-Arg28), though the backbone conformation is 
largely invariant between the two enantiomers. Aside from a network of hydrogen bonds, the structure of 
kB1 is stabilized by the cystine knot motif, which comprises an embedded ring formed by two disulfide 
bonds (CysI-CysIV and CysII-CysV) and their connecting backbone segments as well as a third disulfide bond 
(CysIII-CysVI) that threads through the embedded ring (Figure 4b inset). Figure 4c shows a comparison of 
our structure of L-kB1 with the most recent solution NMR structure of kB1 (PDB ID: 1NB1), showing that 
the overall structures are similar, with minor differences in the precise position of loop 3 (residues Asn15 to 
Gly18) and loop 6 (Thr27 to Val4). Until now, structural studies on kB1 have been performed using NMR; 
initially, some structural features of kB1, such as the cystine knot topology,[37-38] were difficult to 
unambiguously define. Although the connectivity has been resolved on the basis of an analysis of high-field 
NMR data relating to the side-chain angles of the Cys residues,[39] and by a chemical analysis of partially 
reduced species,[40] the crystal structure of kB1 presented here provides conclusive evidence of the disulfide 
bond topology. It is worth noting that the knotted disulfide bond arrangement in combination with the cyclic 
backbone has been shown through mutational studies to underpin the exceptional stability of kB1, which is 
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resistant to chaotropic agents, high temperature, acids, and a range of proteases, including conditions under 
which most proteins denature or degrade.[41] Overall, the remarkable stability of kB1 together with the 
possibility to introduce combinatorial variation within these sequences, make kB1 and other cyclotides 
promising scaffolds for design and development of peptide-based therapeutics. 
 
Aside from being of interest because of its stability, kB1 has various bioactivities that are of interest from an 
agrochemical and/or pharmaceutical perspective. These include insecticidal,[11] uterotonic,[12] HIV 
inhibitory,[13] antimicrobial,[14] cancer cell toxicity,[15] and immunosuppressant activities.[16] We have found 
that the activities of kB1 can be fine-tuned by single-point mutations.[42] For example, the analogue 
[G6A]kB1 is inactive in insecticidal assays whereas [V25A]kB1 maintains activity comparable to the native 
peptide.[42] We were interested in determining the structures of kB1 analogues that have different activity 
profiles, and therefore investigated the use of quasi-racemic crystallography. The X-ray structures of the 
[G6A]kB1 and [V25A]kB1 quasi-racemates were both solved in space group P-1 and are shown in Figure 
5a and 5b, respectively. Interestingly, their unit cells are almost identical to that of the true racemate.  
 
To summarize, we have determined the X-ray crystal structures of three prototypical cyclic disulfide-rich 
peptides as well as two quasi-racemic structures. X-ray diffraction data were acquired to 1.25 Å resolution 
for the racemic mixture of SFTI-1, 1.70 Å resolution for the racemic mixture of cVc1.1, and 1.90 Å 
resolution for the racemic mixture of kB1, 1.25 Å resolution for the quasi-racemic mixture of [G6A]kB1, 
and 2.30 Å resolution for the quasi-racemic mixture of [V25A]kB1. Inspection of the structures revealed 
that the peptides form compact tertiary folds that are stabilized by disulfide bonds, sometimes forming an 
intricate topology. 
 
In addition to providing high resolution structural information, the racemic crystallography approach made it 
possible to crystallize a range of cyclic disulfide-rich peptides and to elucidate the structures of both 
enantiomeric forms. SFTI-1, cVc1.1 and kB1 represent a series of cyclic disulfide-rich peptides with 
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increasing size and complexity, i.e. from a 14-mer peptide with one disulfide bond, to a 29-mer peptide with 
three knotted disulfide bonds. Therefore, the racemic crystallization strategy is likely to be useful for cyclic 
disulfide-rich peptide scaffolds between and beyond the examples used here. Additionally, the quasi-racemic 
crystallography approach was also successful. We postulate that the quasi-racemic crystallization strategy is 
likely to be useful for other chemically engineered peptides. For example, it might be possible to use quasi-
racemic crystallization to determine the X-ray structure of a grafted cyclic disulfide-rich peptide by 
partnering the L-grafted peptide with the D-peptide scaffold, or a cyclic disulfide-rich peptide with a 
chemical conjugate (e.g. to be used as a diagnostic contrasting agent) as has been attempted recently for a 
glycosylated protein.[32] We believe that racemic and quasi-racemic crystallography of cyclic disulfide-rich 
peptides can be widely applied in the field of cyclic peptide structural biology. 
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Tables 
 
Table 1: Sequences and activity of cyclic disulfide-rich peptides studied in this work.  
Peptide  
  (SS bonds) 
Sequencea Peptide 
Class 
Activity/Applications 
SFTI-1 
  (1 SS) 
 
 
BBI-like 
trypsin 
inhibitor 
(H. annus) 
Trypsin inhibition,[8] 
drug design scaffold 
cVc1.1 
  (2 SS) 
 
Conotoxin 
(synthetic)  
Oral activity against 
neuropathic pain,[9] 
drug design scaffold 
kB1 
  (3 SS) 
 
Cyclotide 
native 
(O. affinis) 
Pesticidal,[11] anti-
HIV,[13] other 
activities,[12, 14-15] 
drug design scaffold 
[G6A]kB1 
  (3 SS)  
Cyclotide 
(synthetic) 
Drug design scaffold 
[V25A]kB1 
  (3 SS)  
Cyclotide 
(synthetic) 
Drug design scaffold 
aCysteines are labeled with Roman numerals. The residues that have been mutated in [G6A]kB1 and [V25A]kB1 are shaded. 
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Figures 
 
 
Figure 1: Circular dichroism (CD) spectra of L- and D-enantiomers of SFTI-1, cVc1.1 and kB1. CD 
spectra of the two a) SFTI-1 enantiomers, b) cVc1.1 enantiomers, and c) kB1 enantiomers in water. CD 
spectra for the two enantiomers of each peptide mixed together in equal ratios are also shown.  
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Figure 2: Racemic crystallography of SFTI-1. a) Unit cell of the true racemate in space group P-3 with 
ribbon representations of the cyclic peptide molecules. The D-enantiomers (in orange) and the L-enantiomers 
(in grey) are labeled. The disulfide bonds are shown in yellow as stick representations. b) Ribbon 
representation of the D-SFTI-1 (orange) with the disulfide bond shown (yellow); Inset: 2Fo-Fc electron 
density map of the CysI-CysII disulfide bond shown contoured at a σ level of 1.0. c) Surface representation 
of the trimer of D-SFTI-1 with the hydrophobic residues colored in orange. d) Ribbon representation of the 
trimer of D-SFTI-1 with the side-chains of hydrophobic residues shown in orange. e) Superposition of L-
SFTI-1 determined here (in orange) with the trypsin-bound structure (in grey; PDB ID: 1SFI). 
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Figure 3: Racemic crystallography of cVc1.1. a) Unit cell of the true racemate in space group Pbca with 
ribbon representations of the cyclic peptide molecules. A pair of the L-enantiomer (in blue) and D-
enantiomer (in grey) is labeled. The disulfide bonds are also shown as stick representations in yellow. b and 
c) Ribbon representations of L-cVc1.1 (blue) and D-cVc1.1 (grey); Inset of b): the packing interface of the 
D- and L-enantiomers; Inset of c) 2Fo-Fc electron density map of the CysI-CysIII and CysII-CysIV disulfide 
bonds shown contoured at a σ level of 1.0. d) Superposition of L-cVc1.1 (blue) with the solution NMR 
structure of L-cVc1.1 (grey). The cysteines are labeled with Roman numerals and the loops are also labeled. 
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Figure 4: Racemic crystallography of kB1. a) Unit cell of the true racemate in space group P-1 with 
ribbon representations of the cyclic peptide molecules. The L-enantiomer (in green) and D-enantiomers (in 
grey) are labeled. The disulfide bonds are also shown as stick representations in yellow. b) Ribbon 
representations of L-kB1 (green) and D-kB1 (grey); Inset: 2Fo-Fc electron density map of the cystine knot 
shown contoured at a σ level of 1.0. c) Superposition of L-kB1 (green) with the solution NMR structure of L-
kB1 (grey; PDB ID: 1NB1). The cysteines are labeled with Roman numerals and the loops are also labeled. 
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Figure 5: Quasi-racemic crystallography of [G6A]kB1 and [V25A]kB1. a) Ribbon representations of L-
[G6A]kB1 (dark green) and D-kB1 (grey). b) Ribbon representations of L-[V25A]kB1 (dark green) and D-
kB1 (grey). The disulfide bonds are shown in yellow and the cysteines are labeled with Roman numerals. 
The residues that were mutated are indicated. 
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